Emerging Cellular Therapies for Anti-myeloperoxidase Vasculitis and Other Autoimmune Diseases

Odobasic, Dragana; Holdsworth, Stephen R.

doi:10.3389/fimmu.2021.642127

Cited by 7 publications

(4 citation statements)

References 115 publications

(174 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, further HLA genotyping and association studies in a larger number of samples may reveal a relationship between the HLA haplotype and diabetes risk. MPO-AAV is a life-threatening autoimmune disease which causes severe inflammation and destruction of small blood vessels, mainly in the kidneys of people older 50 years 33 . Given that neuroinflammation significantly contributes to the onset and progression of LOAD 10 , 13 , this result suggests that the presence of the DRB1*09:01-DQB1*03:03 haplotype might confer an increased risk of LOAD, even in adults without the APOE 4 allele.…”

Section: Discussionmentioning

confidence: 99%

The HLA-DRB109:01-DQB103:03 haplotype is associated with the risk for late-onset Alzheimer’s disease in APOE $${{\varepsilon }}$$4–negative Japanese adults

Shigemizu,

Fukunaga,

Yamakawa

et al. 2024

npj Aging

View full text Add to dashboard Cite

Late-onset Alzheimer’s disease (LOAD) is the most common cause of dementia among those older than 65 years. The onset of LOAD is influenced by neuroinflammation. The human leukocyte antigen (HLA) system is involved in regulating inflammatory responses. Numerous HLA alleles and their haplotypes have shown varying associations with LOAD in diverse populations, yet their impact on the Japanese population remains to be elucidated. Here, we conducted a comprehensive investigation into the associations between LOAD and HLA alleles within the Japanese population. Using whole-genome sequencing (WGS) data from 303 LOAD patients and 1717 cognitively normal (CN) controls, we identified four-digit HLA class I alleles (A, B, and C) and class II alleles (DRB1, DQB1, and DPB1). We found a significant association between the HLA-DRB1*09:01-DQB1*03:03 haplotype and LOAD risk in APOE$${\rm{\varepsilon }}$$ ε 4–negative samples (odds ratio = 1.81, 95% confidence interval = 1.38–2.38, P = 2.03$${\times 10}^{-5}$$ × 10 − 5 ). These alleles not only showed distinctive frequencies specific to East Asians but demonstrated a high degree of linkage disequilibrium in APOE$${\rm{\varepsilon }}$$ ε 4–negative samples (r2 = 0.88). Because HLA class II molecules interact with T-cell receptors (TCRs), we explored potential disparities in the diversities of TCR α chain (TRA) and β chain (TRB) repertoires between APOE$${\rm{\varepsilon }}$$ ε 4–negative LOAD and CN samples. Lower diversity of TRA repertoires was associated with LOAD in APOE$${\rm{\varepsilon }}$$ ε 4-negative samples, irrespective of the HLA DRB1*09:01-DQB1*03:03 haplotype. Our study enhances the understanding of the etiology of LOAD in the Japanese population and provides new insights into the underlying mechanisms of its pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

The HLA-DRB109:01-DQB103:03 haplotype is associated with the risk for late-onset Alzheimer’s disease in APOE $${{\varepsilon }}$$4–negative Japanese adults

Shigemizu,

Fukunaga,

Yamakawa

et al. 2024

npj Aging

View full text Add to dashboard Cite

show abstract

“…The elevated levels of MPO have been detected in atherosclerotic lesions, and studies suggest that it may serve as a marker for increased cardiovascular risk. MPO is considered a potential biomarker for assessing inflammation and oxidative stress associated with atherosclerosis, and its measurement in blood samples is being explored in clinical research [79,80].…”

Section: Biomarkers In Atherosclerosismentioning

confidence: 99%

Photodynamic Therapy for Atherosclerosis

Mytych,

Bartusik-Aebisher,

Łoś

et al. 2024

IJMS

View full text Add to dashboard Cite

Atherosclerosis, which currently contributes to 31% of deaths globally, is of critical cardiovascular concern. Current diagnostic tools and biomarkers are limited, emphasizing the need for early detection. Lifestyle modifications and medications form the basis of treatment, and emerging therapies such as photodynamic therapy are being developed. Photodynamic therapy involves a photosensitizer selectively targeting components of atherosclerotic plaques. When activated by specific light wavelengths, it induces localized oxidative stress aiming to stabilize plaques and reduce inflammation. The key advantage lies in its selective targeting, sparing healthy tissues. While preclinical studies are encouraging, ongoing research and clinical trials are crucial for optimizing protocols and ensuring long-term safety and efficacy. The potential combination with other therapies makes photodynamic therapy a versatile and promising avenue for addressing atherosclerosis and associated cardiovascular disease. The investigations underscore the possibility of utilizing photodynamic therapy as a valuable treatment choice for atherosclerosis. As advancements in research continue, photodynamic therapy might become more seamlessly incorporated into clinical approaches for managing atherosclerosis, providing a blend of efficacy and limited invasiveness.

show abstract

“… 194 Emerging cell therapies with tolerogenic dendritic cells, regulatory T cells (CAR-T cells), and stem cells (namely human amniotic epithelial cells) will probably emerge due to their selective immunosuppressive capacity. 195 In addition, the use of cytokines for the treatment of autoimmune rheumatic diseases has been studied. 196 It was shown that administration of low dose IL-2 allows expansion of T reg repertoire without effector T cell activation.…”

Section: Treatmentmentioning

confidence: 99%

A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis

Moura

Branco

Martins-Martinho

et al. 2022

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

In the past decade, unprecedented progress has been made in understanding the pathogenesis, diagnosis, assessment, and treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). International collaborations and input from several fields (e.g. immunology, rheumatology, and nephrology) have been critical for analyzing demographics, disease manifestations, and outcomes in clinical research studies. Such efforts opened new avenues for generating novel questions and rationale to design better clinical trials. In addition, clinical research has been a source of several biological discoveries and the starting point for knowledge seeking on the pathophysiology of AAV. Interestingly, the blending of clinical and basic research provides a platform for personalized medicine. Despite recent revisions on AAV classification, the incorporation of new findings on disease genetics and immunologic responses may soon result in changes in clinical practice. These advances will enhance the selection of more specific and targeted therapies. However, current unmet needs in the management of AAV are still sizable and heavily impact long-term survival. Especially, frequent relapses, damage accrual, and high morbidity contribute to poor outcomes. Finally, the lack of defined biomarkers for disease activity and the prognosis is a permanent challenge in AAV research. Our work provides an overview of the current state of the art in AAV literature and suggests bridges for the remaining knowledge gaps. It offers potential future directions for the clinical assessment, management, and research in the field toward a more personalized medicine approach.

show abstract

Emerging Cellular Therapies for Anti-myeloperoxidase Vasculitis and Other Autoimmune Diseases

Cited by 7 publications

References 115 publications

The HLA-DRB109:01-DQB103:03 haplotype is associated with the risk for late-onset Alzheimer’s disease in APOE $${{\varepsilon }}$$4–negative Japanese adults

The HLA-DRB109:01-DQB103:03 haplotype is associated with the risk for late-onset Alzheimer’s disease in APOE $${{\varepsilon }}$$4–negative Japanese adults

Photodynamic Therapy for Atherosclerosis

A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis

Contact Info

Product

Resources

About

Emerging Cellular Therapies for Anti-myeloperoxidase Vasculitis and Other Autoimmune Diseases

Cited by 7 publications

References 115 publications

The HLA-DRB1*09:01-DQB1*03:03 haplotype is associated with the risk for late-onset Alzheimer’s disease in APOE $${{\varepsilon }}$$4–negative Japanese adults

The HLA-DRB1*09:01-DQB1*03:03 haplotype is associated with the risk for late-onset Alzheimer’s disease in APOE $${{\varepsilon }}$$4–negative Japanese adults

Photodynamic Therapy for Atherosclerosis

A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis

Contact Info

Product

Resources

About

The HLA-DRB109:01-DQB103:03 haplotype is associated with the risk for late-onset Alzheimer’s disease in APOE $${{\varepsilon }}$$4–negative Japanese adults

The HLA-DRB109:01-DQB103:03 haplotype is associated with the risk for late-onset Alzheimer’s disease in APOE $${{\varepsilon }}$$4–negative Japanese adults